What one share of Kiniksa Pharmaceuticals International holds
We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation.
Kiniksa Pharmaceuticals International’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $9.36 |
|---|---|
| Profit | $0.91 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $2.04 |
| Cash and investments | $2.48 |
| Book value | $7.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$35.85 | — | — | — | −$49.57 |
| 2018 | — | −$3.49 | $0.18 | −$2.92 | — | $9.45 |
| 2019 | — | −$2.99 | $0.06 | −$2.99 | — | $4.17 |
| 2020 | — | −$2.61 | $0.00 | −$2.21 | — | $5.04 |
| 2021 | $0.56 | −$2.30 | $0.01 | −$1.85 | — | $2.70 |
| 2022 | $3.13 | $2.60 | $0.00 | $0.08 | — | $5.71 |
| 2023 | $3.76 | $0.20 | $0.00 | $0.18 | — | $6.26 |
| 2024 | $5.93 | −$0.60 | $0.00 | $0.36 | — | $6.14 |
| 2025 | $8.58 | $0.75 | $0.02 | $1.73 | — | $7.65 |
Common questions about Kiniksa Pharmaceuticals International
How much does one share of Kiniksa Pharmaceuticals International earn?
Over the last 12 months, each share of Kiniksa Pharmaceuticals International earned $0.91 of profit on $9.36 of sales, keeping about 10¢ of every $1 (profit margin).
Does Kiniksa Pharmaceuticals International pay a dividend?
Kiniksa Pharmaceuticals International didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Kiniksa Pharmaceuticals International’s book value per share?
Kiniksa Pharmaceuticals International’s book value is $7.92 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of March 31, 2026.
How much cash and debt does each share of Kiniksa Pharmaceuticals International have?
Each share of Kiniksa Pharmaceuticals International has $2.48 of cash and investments, as of March 31, 2026.
What is Kiniksa Pharmaceuticals International’s free cash flow per share?
$2.04 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Kiniksa Pharmaceuticals International bought back shares?
Kiniksa Pharmaceuticals International’s share count rose about 4264% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.